{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T00:06:52Z","timestamp":1760918812361,"version":"build-2065373602"},"reference-count":61,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.bmc.2023.117273","type":"journal-article","created":{"date-parts":[[2023,4,3]],"date-time":"2023-04-03T21:15:30Z","timestamp":1680556530000},"page":"117273","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Optimization of physicochemical properties of pyrrolidine GPR40 AgoPAMs results in a differentiated profile with improved pharmacokinetics and reduced off-target activities"],"prefix":"10.1016","volume":"85","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3689-5451","authenticated-orcid":false,"given":"Elizabeth A.","family":"Jurica","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ximao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristin N.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lauren E.","family":"Haque","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard A.","family":"Rampulla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3146-8485","authenticated-orcid":false,"given":"Arvind","family":"Mathur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gary","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong","family":"Cai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carrie","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lori K.","family":"Kunselman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas M.","family":"Antrilli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael B.","family":"Hicks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qin","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth A.","family":"Dierks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsu","family":"Apedo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Douglas B.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimberly A.","family":"Foster","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary Ellen","family":"Cvijic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reshma","family":"Panemangalore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Purnima","family":"Khandelwal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason J.","family":"Wilkes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bradley A.","family":"Zinker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donald G.","family":"Robertson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evan B.","family":"Janovitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Galella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-Xin","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thangeswaran","family":"Ramar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prasada Rao","family":"Jalagam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ramya","family":"Jayaram","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0630-211X","authenticated-orcid":false,"given":"Jean M.","family":"Whaley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-7351-1261","authenticated-orcid":false,"given":"Joel C.","family":"Barrish","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey A.","family":"Robl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9434-8053","authenticated-orcid":false,"given":"William R.","family":"Ewing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruce A.","family":"Ellsworth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmc.2023.117273_b0005","unstructured":"IDF Diabetes Atlas, 9th ed. International Diabetes Federation: Brussels, Belgium; 2019."},{"key":"10.1016\/j.bmc.2023.117273_b0010","doi-asserted-by":"crossref","unstructured":"Nathan DM. Long-Term Complications of Diabetes Mellitus. N Engl J Med 1993;328:1676\u201385.","DOI":"10.1056\/NEJM199306103282306"},{"key":"10.1016\/j.bmc.2023.117273_b0015","doi-asserted-by":"crossref","first-page":"11303","DOI":"10.1074\/jbc.M211495200","article-title":"The Orphan G Protein-Coupled Receptor GPR40 is Activated by Medium and Long Chain Fatty Acids","volume":"278","author":"Briscoe","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bmc.2023.117273_b0020","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/nature01478","article-title":"Free Fatty Acids Regulate Insulin Secretion from Pancreatic [beta] Cells through GPR40","volume":"422","author":"Itoh","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.bmc.2023.117273_b0025","first-page":"1403","article-title":"TAK-875 Versus Placebo or Glimepiride in Type 2 Diabetes Mellitus: A Phase 2, Randomised, Double-Blind","volume":"379","author":"Burant","year":"2012","journal-title":"Placebo-Controlled Trial Lancet"},{"key":"10.1016\/j.bmc.2023.117273_b0030","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.mce.2016.11.024","article-title":"Gq and Gs signaling acting in synergy to control GLP-1 secretion","volume":"449","author":"Hauge","year":"2017","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.bmc.2023.117273_b0035","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.molmet.2014.10.002","article-title":"GPR40 (FFAR1) \u2013 Combined Gs and Gq signaling in vitro is associated with robust incretin secretagogue action ex vivo and in vivo","volume":"4","author":"Hauge","year":"2015","journal-title":"Mol Metab"},{"key":"10.1016\/j.bmc.2023.117273_b0040","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1124\/mol.117.111369","article-title":"GPR40-mediated G\u03b112 activation by allosteric full agonists highly efficacious at potentiating glucose-stimulated insulin secretion in human islets","volume":"93","author":"Rives","year":"2018","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.bmc.2023.117273_b0045","doi-asserted-by":"crossref","first-page":"21131","DOI":"10.1074\/jbc.M115.644450","article-title":"\u03b2-Arrestin Recruitment and Biased Agonism at Free Fatty Acid Receptor 1","volume":"290","author":"Mancini","year":"2015","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bmc.2023.117273_b0050","doi-asserted-by":"crossref","first-page":"e46300","DOI":"10.1371\/journal.pone.0046300","article-title":"A Potent Class of GPR40 Full Agonists Engages the EnteroInsular Axis to Promote Glucose Control in Rodents","volume":"7","author":"Luo","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.bmc.2023.117273_b0055","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1124\/mol.112.079640","article-title":"Identification and Pharmacological Characterization of Multiple Allosteric Binding Sites on the Free Fatty Acid 1 Receptor","volume":"82","author":"Lin","year":"2012","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.bmc.2023.117273_b0060","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.2337\/db21-0451","article-title":"SCO-267, a GPR40 Full Agonist, Stimulates Islet and Gut Hormone Secretion and Improves Glycemic Control in Humans","volume":"70","author":"Nishizaki","year":"2021","journal-title":"Diabetes"},{"key":"10.1016\/j.bmc.2023.117273_b0065","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1038\/s41467-017-01240-w","article-title":"Structural basis for GPR40 allosteric agonism and incretin stimulation","volume":"9","author":"Ho","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.bmc.2023.117273_b0070","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1038\/nsmb.3417","article-title":"Structural basis for the cooperative allosteric activation of the free fatty acid receptor GPR40","volume":"24","author":"Lu","year":"2017","journal-title":"Nat Struct Mol Biol"},{"key":"10.1016\/j.bmc.2023.117273_b0075","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1021\/acs.jmedchem.6b01559","article-title":"Discovery of Pyrrolidine-Containing GPR40 Agonists: Stereochemistry Effects a Change in Binding Mode","volume":"60","author":"Jurica","year":"2017","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2023.117273_b0080","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1021\/acs.jmedchem.7b00982","article-title":"Discovery of Potent and Orally Bioavailable Dihydropyrazole GPR40 Agonists","volume":"61","author":"Shi","year":"2018","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2023.117273_b0085","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1517\/17460441.2012.714363","article-title":"The influence of lipophilicity in drug discovery and design","volume":"7","author":"Arnott","year":"2012","journal-title":"Expert Opin Drug Discov"},{"key":"10.1016\/j.bmc.2023.117273_b0090","doi-asserted-by":"crossref","first-page":"4872","DOI":"10.1016\/j.bmcl.2008.07.071","article-title":"Physiochemical drug properties associated with in vivo toxicological outcomes","volume":"18","author":"Hughes","year":"2008","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmc.2023.117273_b0095","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1021\/tx200211v","article-title":"Improving Drug Candidates by Design: A Focus on Physicochemical Properties As a Means of Improving Compound Disposition and Safety","volume":"24","author":"Meanwell","year":"2011","journal-title":"Chem Res Toxicol"},{"key":"10.1016\/j.bmc.2023.117273_b0100","doi-asserted-by":"crossref","unstructured":"JChem for Excel, 17.2.1300.1489; ChemAxon: 2008-2017.","DOI":"10.1080\/14697688.2017.1372251"},{"key":"10.1016\/j.bmc.2023.117273_b0105","doi-asserted-by":"crossref","first-page":"3451","DOI":"10.1021\/jm0603825","article-title":"Dependence of Molecular Properties on Proteomic Family for Marketed Oral Drugs","volume":"49","author":"Vieth","year":"2006","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2023.117273_b0110","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1021\/ml1000855","article-title":"Discovery of TAK-875: A Potent, Selective, and Orally Bioavailable GPR40 Agonist","volume":"1","author":"Negoro","year":"2010","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.bmc.2023.117273_b0115","doi-asserted-by":"crossref","first-page":"10891","DOI":"10.1021\/acs.jmedchem.6b00892","article-title":"The Discovery, Preclinical, and Early Clinical Development of Potent and Selective GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus (LY2881835, LY2922083, and LY2922470)","volume":"59","author":"Hamdouchi","year":"2016","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2023.117273_b0120","doi-asserted-by":"crossref","first-page":"6752","DOI":"10.1021\/jm901241e","article-title":"Escape from Flatland: Increasing Saturation as an Approach to Improving Clinical Success","volume":"52","author":"Lovering","year":"2009","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2023.117273_b0125","article-title":"Preparation of dihydropyrazole GPR40 modulators for treating diabetes and related conditions and other diseases","author":"Ellsworth","year":"2014","journal-title":"WO2014078610A1"},{"key":"10.1016\/j.bmc.2023.117273_b0130","article-title":"Preparation of dihydropyrazole GPR40 modulators for treating diabetes and related conditions and other diseases","author":"Ellsworth","year":"2014","journal-title":"WO2014078611A1"},{"key":"10.1016\/j.bmc.2023.117273_b0135","article-title":"Preparation of pyrrolidine GPR40 modulators for treating diabetes and related conditions and other diseases","author":"Ellsworth","year":"2014","journal-title":"WO2014078609A1"},{"key":"10.1016\/j.bmc.2023.117273_b0140","article-title":"Preparation of pyrrolidine GPR40 modulators for the treatment of diabetes and related diseases","author":"Jurica","year":"2015","journal-title":"WO2015171722A1"},{"key":"10.1016\/j.bmc.2023.117273_b0145","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.bmcl.2018.01.013","article-title":"Discovery of a novel potent GPR40 full agonist","volume":"28","author":"Meegalla","year":"2018","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmc.2023.117273_b0150","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1016\/j.bmcl.2019.04.050","article-title":"Design, synthesis and biological evaluation of indane derived GPR40 agoPAMs","volume":"29","author":"Pio","year":"2019","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmc.2023.117273_b0155","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1021\/acsmedchemlett.6b00443","article-title":"Design and Synthesis of Novel, Selective GPR40 AgoPAMs","volume":"8","author":"Plummer","year":"2017","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.bmc.2023.117273_b0160","doi-asserted-by":"crossref","first-page":"e0186033","DOI":"10.1371\/journal.pone.0186033","article-title":"GPR40 partial agonists and AgoPAMs: Differentiating effects on glucose and hormonal secretions in the rodent","volume":"12","author":"Pachanski","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.bmc.2023.117273_b0165","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1021\/acsmedchemlett.8b00444","article-title":"Discovery of a GPR40 Superagonist: The Impact of Aryl Propionic Acid \u03b1-Fluorination","volume":"10","author":"Huang","year":"2019","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.bmc.2023.117273_b0170","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1124\/jpet.118.255885","article-title":"SCO-267, a GPR40 Full Agonist, Improves Glycemic and Body Weight Control in Rat Models of Diabetes and Obesity","volume":"370","author":"Ueno","year":"2019","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.bmc.2023.117273_b0175","doi-asserted-by":"crossref","first-page":"10352","DOI":"10.1021\/acs.jmedchem.0c00843","article-title":"Design and Identification of a GPR40 Full Agonist (SCO-267) Possessing a 2-Carbamoylphenyl Piperidine Moiety","volume":"63","author":"Furukawa","year":"2020","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2023.117273_b0180","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1039\/B607701N","article-title":"Halogen dance reactions\u2014A review","volume":"36","author":"Schn\u00fcrch","year":"2007","journal-title":"Chem Soc Rev"},{"key":"10.1016\/j.bmc.2023.117273_b0185","doi-asserted-by":"crossref","first-page":"3703","DOI":"10.1021\/ol026655h","article-title":"Copper-Catalyzed Arylation of \u03b2-Amino Alcohols","volume":"4","author":"Job","year":"2002","journal-title":"Org Lett"},{"key":"10.1016\/j.bmc.2023.117273_b0190","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1517\/17425255.1.1.91","article-title":"Minimising the potential for metabolic activation in drug discovery","volume":"1","author":"Kalgutkar","year":"2005","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.bmc.2023.117273_b0195","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1002\/bdd.1996","article-title":"A physiologically based pharmacokinetic model to predict the pharmacokinetics of highly protein-bound drugs and the impact of errors in plasma protein binding","volume":"37","author":"Ye","year":"2016","journal-title":"Biopharm Drug Dispos"},{"key":"10.1016\/j.bmc.2023.117273_b0200","doi-asserted-by":"crossref","first-page":"515","DOI":"10.2165\/00003088-200342060-00002","article-title":"Metabolic Stability for Drug Discovery and Development","volume":"42","author":"Masimirembwa","year":"2003","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.bmc.2023.117273_b0205","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1055\/s-1981-29317","article-title":"The Use of Diethyl Azodicarboxylate and Triphenylphosphine in Synthesis and Transformation of Natural Products","volume":"1981","author":"Mitsunobu","year":"1981","journal-title":"Synthesis"},{"key":"10.1016\/j.bmc.2023.117273_b0210","first-page":"1349","article-title":"Development of Neuroendocrine Tumors in the Gastrointestinal Tract of Transgenic Mice. Heterogeneity of Hormone Expression","volume":"136","author":"Rindi","year":"1990","journal-title":"Am J Pathol"},{"key":"10.1016\/j.bmc.2023.117273_b0215","first-page":"4917","article-title":"Early Invasiveness Characterizes Metastatic Carcinoid Tumors in Transgenic Mice","volume":"51","author":"Grant","year":"1991","journal-title":"Cancer Res"},{"key":"10.1016\/j.bmc.2023.117273_b0220","doi-asserted-by":"crossref","first-page":"E37","DOI":"10.1152\/ajpendo.00435.2016","article-title":"GPR40 reduces food intake and body weight through GLP-1","volume":"313","author":"Gorski","year":"2017","journal-title":"Am J Phys Endocrinol Metab"},{"key":"10.1016\/j.bmc.2023.117273_b0225","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.mce.2013.01.009","article-title":"Activation of FFA1 Mediates GLP-1 Secretion in Mice. Evidence for Allosterism at FFA1","volume":"369","author":"Xiong","year":"2013","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.bmc.2023.117273_b0230","doi-asserted-by":"crossref","first-page":"3585","DOI":"10.1210\/endo.136.8.7628397","article-title":"Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV","volume":"136","author":"Kieffer","year":"1995","journal-title":"Endocrinology"},{"key":"10.1016\/j.bmc.2023.117273_b0235","doi-asserted-by":"crossref","first-page":"389","DOI":"10.3389\/fendo.2019.00389","article-title":"Clinical Use of DPP-4 Inhibitors","volume":"10","author":"Gallwitz","year":"2019","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.bmc.2023.117273_b0240","doi-asserted-by":"crossref","first-page":"80","DOI":"10.3389\/fendo.2019.00080","article-title":"Physiology and Pharmacology of DPP-4 in Glucose Homeostasis and the Treatment of Type 2 Diabetes","volume":"10","author":"Deacon","year":"2019","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.bmc.2023.117273_b0245","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1110\/ps.073253208","article-title":"Involvement of DPP-IV catalytic residues in enzyme\u2013saxagliptin complex formation","volume":"17","author":"Metzler","year":"2008","journal-title":"Protein Sci"},{"key":"10.1016\/j.bmc.2023.117273_b0250","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0009-2797(03)00020-6","article-title":"Acyl glucuronide reactivity in perspective: biological consequences","volume":"145","author":"Bailey","year":"2003","journal-title":"Chem-Biol Interact"},{"key":"10.1016\/j.bmc.2023.117273_b0255","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00007691-200302000-00001","article-title":"Acyl Glucuronide Drug Metabolites: Toxicological and Analytical Implications","volume":"25","author":"Shipkova","year":"2003","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.bmc.2023.117273_b0260","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1208\/s12248-010-9203-3","article-title":"The Use of Biorelevant Dissolution Media to Forecast the In Vivo Performance of a Drug","volume":"12","author":"Klein","year":"2010","journal-title":"AAPS J"},{"key":"10.1016\/j.bmc.2023.117273_b0265","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1023\/A:1011984216775","article-title":"Dissolution Testing as a Prognostic Tool for Oral Drug Absorption: Immediate Release Dosage Forms","volume":"15","author":"Dressman","year":"1998","journal-title":"Pharm Res"},{"key":"10.1016\/j.bmc.2023.117273_b0270","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.1021\/jm401859b","article-title":"High Throughput Method for the Indirect Detection of Intramolecular Hydrogen Bonding","volume":"57","author":"Goetz","year":"2014","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2023.117273_b0275","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1021\/js9803205","article-title":"MDCK (Madin\u2013Darby canine kidney) cells: A tool for membrane permeability screening","volume":"88","author":"Irvine","year":"1999","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.bmc.2023.117273_b0280","doi-asserted-by":"crossref","first-page":"429","DOI":"10.2165\/00003088-199120060-00001","article-title":"Nonlinear Pharmacokinetics","volume":"20","author":"Ludden","year":"1991","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.bmc.2023.117273_b0285","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1007\/s11892-014-0492-2","article-title":"Lipotoxicity in the Pancreatic Beta Cell: Not Just Survival and Function, but Proliferation as Well?","volume":"14","author":"Sharma","year":"2014","journal-title":"Curr Diabetes Rep"},{"key":"10.1016\/j.bmc.2023.117273_b0290","doi-asserted-by":"crossref","first-page":"e66744","DOI":"10.1371\/journal.pone.0066744","article-title":"DC260126: A Small-Molecule Antagonist of GPR40 that Protects against Pancreatic \u03b2-Cells Dysfunction in db\/db Mice","volume":"8","author":"Sun","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.bmc.2023.117273_b0295","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.bbrc.2009.10.004","article-title":"A novel class of antagonists for the FFAs receptor GPR40","volume":"390","author":"Hu","year":"2009","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.bmc.2023.117273_b0300","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1038\/sj.bjp.0706770","article-title":"Pharmacological regulation of insulin secretion in MIN6 cells through the fatty acid receptor GPR40: identification of agonist and antagonist small molecules","volume":"148","author":"Briscoe","year":"2006","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.bmc.2023.117273_b0305","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.bbrc.2006.12.193","article-title":"GPR40 is expressed in glucagon producing cells and affects glucagon secretion","volume":"354","author":"Flodgren","year":"2007","journal-title":"Biochem Biophys Res Commun"}],"container-title":["Bioorganic & Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089623001219?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089623001219?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T01:21:59Z","timestamp":1760836919000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0968089623001219"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":61,"alternative-id":["S0968089623001219"],"URL":"https:\/\/doi.org\/10.1016\/j.bmc.2023.117273","relation":{},"ISSN":["0968-0896"],"issn-type":[{"type":"print","value":"0968-0896"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Optimization of physicochemical properties of pyrrolidine GPR40 AgoPAMs results in a differentiated profile with improved pharmacokinetics and reduced off-target activities","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmc.2023.117273","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"117273"}}